Pupo RA, Arias AD, Ayón TY, Grass HN

Language: Spanish
References: 9
Page: 613-619
PDF size: 381.54 Kb.

ABSTRACT

Prostate cancer commonly affects men after age 50; the evolution is slow, with histological variety of adenocarcinoma present in approximately 95%. It is not frequent to find histological differentiations of neuroendocrine type. A 29-year-old man from Banes was presented with perineal pain and discomfort during the sexual intercourse. The patient was assisted at Urology Consultation of the Lenin Hospital in Holguín where he was treated as a prostatic inflammatory process and antimicrobial and anti-inflammatory drugs were used. Other studies were not obtained and the prostate specific antigen reported high values; rectal examination revealed changes in consistency, a prostate biopsy was suggested, revealing a neuroendocrine adenocarcinoma of the prostate. When consulting the literature, specific therapeutic protocols were not available for these cases, but generally etoposide and cisplatin were used. The evolutions was torpid and rapid the appearance of bone, hepatic, mediastinal and ascites metastases as well as respiratory distress until the patient´s death, at 19 months the diagnosis was defined.

REFERENCES

1. Tarján M. Prognostic significance of focal neuroendocrine differentiation in prostate cancer: cases with autopsy-verified cause of death. Indian J Urol. 2010[citado 27 mar 2017]; 26(1):41-45. Disponible en: http://www.indianjurol.com/text.asp?2010/26/1/41/60442

2. Glück G, Mihai M, Stoica R, Andrei R, Sinescu I. Prostate cancer with neuroendocrine differentiation-case report. J Med Life. 2012[citado 26 mar 2017]; 5(1):101-104. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3307067/pdf/JMedLife-05-101.pdf

3. Epstein JI1, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014[citado 27 mar 2017]; 38(6):756-767. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112087/

4. Arenas Reyes NJ, Manuel Moreno LA, Carrillo Rodríguez AP, Fonseca Buitrago CL, Daza Almendrales FP. Diferenciación neuroendocrina en cáncer de próstata. Revisión de la literatura. Rev Urol Colombiana. 2014[citado 26 mar 2017]; 23(1):39-43. Disponible en: http://www.redalyc.org/html/1491/149131193008/

5. Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis. J Clin Oncol. 2014[citado 27 mar 2017]; 32(30): 3383-3390. Disponible en: http://ascopubs.org/doi/abs/10.1200/jco.2013.54.3553

6. Martínez Cornelio A, González Pérez J, Tabares García FJ, Ramos Salgado F, Alvarado Cabrero I, Hernández Toriz N. Bloqueo androgénico total en el manejo del cáncer de próstata neuroendocrino. Cir Ciruj. 2009[citado 26 mar 2017]; 77(4):293-299. Disponible en: http://www.redalyc.org/articulo.oa?id=66211210007

7. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol. 2014[citado 27 mar 2017]; 92(1):11-24. Disponible en: http://www.croh-online.com/article/S1040-8428%2814%2900087-0/pdf

8. Agüero Gómez JL, Cepero Olivera PJ, Duarte Vilariño A, García Cepero D. Microcitoma de próstata o tumor de células pequeñas. Un nuevo reporte. MEDICIEGO. 2014[citado 27 mar 2017]; 20(Supl 1). Disponible en: http://bvs.sld.cu/revistas/mciego/vol20_Supl%201_14/casos/T13.html

9. Reyes Rodríguez S, Vega Jiménez J, Rodríguez Pérez D. Síndrome mediastinal como forma de presentación de un adenocarcinoma prostático. CCM. 2016 [citado 4 ene 2017]; 20(3). Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/2295